America’s obesity crisis extends beyond humans — studies suggest that around 60% of dogs and cats nationwide are overweight. The consequences are far from fluffy. Those extra pounds can lead to serious health issues, sky-high vet bills and fewer years with your furry friend.

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious form of fatty liver disease.

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff numbers over five years.

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don’t go through insurance.

Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled off its GLP-1 throne. In a statement to Reuters, the Danish conglomerate admitted that it "currently [has] a hiring freeze in non-business critical areas.

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications. Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service,

Novo Nordisk is shaking up the prescription drug market by slashing the price of Ozempic for uninsured Americans. The company announced that patients who pay out of pocket can now […] The post Ozempic Price Drop: $1,